Transplanting Supersites of HIV-1 Vulnerability

Tongqing Zhou¹,³, Jiang Zhu¹,³, Yongping Yang¹, Jason Gorman¹, Gilad Ofek¹, Sanjay Srivatsan¹, Aliaksandr Druż¹, Christopher R. Lees¹, Gabriel Lu¹, Cinque Soto¹, Jonathan Stuckey¹, Dennis R. Burton²,³, Wayne C. Koff⁴, Mark Connors⁵, Peter D. Kwon¹ *

¹Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, ²Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Design, The Scripps Research Institute, La Jolla, California, United States of America, ³Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America, ⁴International AIDS Vaccine Initiative (IAVI), New York, New York, United States of America, ⁵HIV-Specific Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

Abstract

One strategy for isolating or eliciting antibodies against a specific target region on the envelope glycoprotein trimer (Env) of the human immunodeficiency virus type 1 (HIV-1) involves the creation of site transplants, which present the target region on a heterologous protein scaffold with preserved antibody-binding properties. If the target region is a supersite of HIV-1 vulnerability, recognized by a collection of broadly neutralizing antibodies, this strategy affords the creation of “supersite transplants”, capable of binding (and potentially eliciting) antibodies similar to the template collection of effective antibodies. Here we transplant three supersites of HIV-1 vulnerability, each targeted by effective neutralizing antibodies from multiple donors. To implement our strategy, we chose a single representative antibody against each of the target supersites: antibody 10E8, which recognizes the membrane-proximal external region (MPER) on the HIV-1 gp41 glycoprotein; antibody P9G, which recognizes variable regions one and two (V1V2) on the HIV-1 gp120 glycoprotein; and antibody PGT128 which recognizes a glycopeptide supersite in variable region 3 (glycan V3) on gp120. We used a structural alignment algorithm to identify suitable acceptor proteins, and then designed, expressed, and tested antigenically over 100 supersite transplants in a 96-well microtiter-plate format. The majority of the supersite transplants failed to maintain the antigenic properties of their respective template supersite. However, seven of the glycan V3-supersite transplants exhibited nanomolar affinity to effective neutralizing antibodies from at least three donors and recapitulated the mannose9-N-linked glycan requirement of the template supersite. The binding of these transplants could be further enhanced by placement into self-assembling nanoparticles. Essential elements of the glycan V3 supersite, embodied by as few as 3 N-linked glycans and 25 Env residues, can be segregated into acceptor scaffolds away from the immune-evading capabilities of the rest of HIV-1 Env, thereby providing a means to focus the immune response on the scaffolded supersite.

Introduction

Antibody isolation and immunogen design are critical components in the current global effort to design an effective vaccine against the human immunodeficiency virus type 1 (HIV-1) (reviewed in [1,2]). The HIV-1 viral spike is metastable and protected from antibody recognition by multiple overlapping mechanisms of immune evasion [3–8]. A plethora of antibodies are elicited against the viral spike or its component subunits, gp120 and gp41, early in natural infection or after vaccination, but virtually none are capable of broad and potent neutralization. Nevertheless, after 2–3 years, the human immune system does generate – in ~20% of HIV-1-infected individuals – effective broadly neutralizing HIV-1 antibodies [9,10], with about half of chronically infected donors showing antibodies of neutralization breadth [11–16]. Substantial effort has been mounted to isolate such antibodies (to understand their immune mechanisms of effective HIV-1 recognition) and to elicit similar antibodies (to protect prophylactically against HIV-1 infection). The difficulty is that, in sera, broadly neutralizing antibodies exist among a much larger number of Env-reactive antibodies with poor or no neutralizing capacity, and immunization with Env variants has not succeeded in eliciting broadly protective responses. There is
thus a need for probes to bind specifically to desired effective antibodies and for immunogens to elicit them.

HIV-1 Env contains many immunodominant epitopes recognized by non-neutralizing antibodies, which greatly outnumber the desired effectively neutralizing antibodies. One strategy to circumvent this problem involves the development of antibody-epitope scaffolds [17–23], in which the residues recognized by a template antibody are separated from the rest of Env through transplantation to a heterologous protein scaffold, while retaining high affinity to the template antibody (Fig. 1, left). However, because the immune system generates a highly diverse immune response in each individual, an epitope scaffold capable of only binding to a very small proportion of neutralizing antibodies may be too specific to identify antibodies in diverse sera or to elicit an effective immune response. Rather, a focus on antigenic mimics of supersites of Env vulnerability, sites on the virus recognized by multiple highly effective neutralizing antibodies from multiple infected donors (reviewed in [24]), might recapitulate the ability of the template supersite to be recognized by antibodies from diverse sera and to elicit similar effective antibodies upon inoculation (Fig. 1, right).

Here we present a supersite-transplantation strategy that (1) used a structural alignment algorithm to identify acceptor scaffolds, (2) employed a 96-well expression platform to facilitate experimental screening of transplants, and (3) validated transplantation with broadly neutralizing antibodies from multiple donors. We screened three HIV-1 supersites of vulnerability to neutralizing antibody. With each of the three sites, we and others had previously determined at least one broadly neutralizing antibody bound to the target supersites. Our results demonstrate that a scaffolding-transplantation algorithm, which allows for a limited degree of structural variation in epitope matching, can identify proteins with suitable backbone geometry to accommodate a site of interest, and that a combined computational-experimental strategy offers an efficient method for the design and screening of probes and immunogen candidates. Furthermore, we provide insight into the glycan V3 supersite [25], perhaps the region of HIV-1 Env most commonly recognized by broadly neutralizing antibodies elicited in the first 2–3 years of infection. Notably, as little as 25 HIV-1 Env amino acids – when properly scaffolded – are able to recapitulate much of the antigenicity of this important Env region of HIV-1 vulnerability to neutralizing antibody.

Figure 1. Supersite transplants. Select locations of an antigen may comprise supersites of vulnerability, each of which is comprised of the overlapping epitopes of effective neutralizing antibodies that arise commonly in multiple donors as a result of the immune response to natural infection. One such site, surrounded by a dotted outline with epitopes shown as colored circles, is depicted at top. Supersite transplantation involves the placement of the supersite into a protein scaffold capable of preserving recognition to broadly neutralizing antibodies, elicited in multiple donors (right). By contrast, epitope scaffolds involve the transplantation of an epitope targetted by a single rare or subdominant antibody (left). doi:10.1371/journal.pone.0099881.g001
Results

Supersite transplantation

The essence of supersite transplantation or scaffolding strategies lies first in the assumption that there exist a sufficient number of proteins in the structure database suitable for presenting the epitope or Env site of interest, and second in the assumption that the antigenic properties of a target supersite – which may encompass a relatively large portion of Env – can be recapitulated in a structurally constrained subportion of the template site. As shown in recent studies [17–23], generally only a few scaffolded epitopes have the desired antigenic profile, likely due to the small number of scaffolds obtained or to expression problems with epitope scaffolds caused by the grafting of a foreign epitope.

We used TM-align [26], a structural alignment algorithm, to search for suitable scaffolds in a culled database of protein structures [Fig. S1]. In contrast with other widely used methods [27,28], TM-align uses a scoring scheme that emphasizes global similarity in structure over local deviations as is typically employed when using root-mean-square deviation (RMSD). Since our ultimate goal was to graft the transplanted region onto a selected scaffold, we used a steric clash filter with van der Waals and DFIRE statistical potentials [29] to ensure that selected scaffolds could accommodate the transplanted region after grafting.

TM-align-identified scaffolds were evaluated for their fitness to accept the HIV-1 transplant based on RMSD, clash score, and a solvent accessibility ratio of greater than 40 after transplantation (see Methods). The next sections provide details on transplantation of three supersites of HIV-1 vulnerability: the membrane-proximal external region (MPER) on HIV-1 gp41; variable regions 1 and 2 (V1V2) on the HIV-1 gp120 envelope glycoprotein, and the conserved glycan base of variable region 3 (glycan V3) also on gp120.

MPER-supersite transplants

Antibodies recognizing the membrane-proximal external region (MPER) on gp41 [Fig. 2a], such as 2F5 [30] and 4E10 [31,32] were among the earliest broadly neutralizing HIV-1 antibodies isolated. The more recent isolation of the MPER-specific antibody 10E8 [33] – which neutralizes >98% of tested viruses, shows no signs of autoreactivity, and binds to an epitope that overlaps that of 4E10 – confirms the MPER as an HIV-1 supersite of vaccine interest. The structure of 10E8 in complex with a peptide encompassing the entire 28-residue gp41 MPER (residues 656-683) was previously determined at a resolution of 2.1 Å [33]. The structure of 10E8-bound MPER was found to be comprised of two helices, with the C-terminal helix forming the primary contacts with 10E8 and the hinge region between the two helices forming additional contacts with the second complementarity-determining region of the 10E8 heavy chain (CDR H2). Structural analysis and binding experiments revealed that the minimal 10E8 epitope is likely located within residues 668-683 of the MPER peptide [33], which overlaps considerably with the 4E10, Z13, and CH12 epitopes [34–36].

Through use of the structural alignment algorithm, two definitions of the 10E8-defined target site were explored to search for suitable acceptor scaffolds: one comprising gp41 residues 659–684 as in chain P in the crystal structure (PDB ID 4G6F) [33], and the other comprising gp41 residues 664–684, composed predominantly of the C-terminal helix and hinge regions as in chain P (Fig. 2b). The Cα RMSD cutoff used in epitope matching was set to 3 Å in the first scaffolding search and to 2 Å in the second search. Six scaffolds were identified with backbone geometry resembling the full 10E8 epitope (Table 1), and for each of these, 4–5 variants were designed to graft the minimal epitope, the minimal epitope plus hinge, and the full epitope (Table S1 in File S1). In total, 27 MPER-supersite transplants were obtained from the search using the full epitope. For the search using only the C-terminal helix and hinge region of the epitope, 13 parent scaffolds, or 21 including variants thereof, were obtained (Table 1). The 47 transplants from both searches were expressed in HEK293T cells in a 96-well microplate format, with a 2F5 scaffold (2F5-ES2) [17] used as control. Expression levels were quantitated by bio-layer interferometry using anti-penta-his biosensors. Overall, the MPER-supersite transplants showed low expression, most likely attributed to the exposed hydrophobic surface [Fig. 2c, top panel]. When tested for 10E8 binding, three parent supersite transplants derived from PDB IDs 3C3H, 3MHS [37] and 3AGJ [38], heretofore referred to as MPER-ST01, MPER-ST02, and MPER-ST03, respectively, showed high reactivity in ELISA assays [Fig. 2c, bottom panel], suggesting that the 10E8 epitope was indeed present in these transplants. Two of the transplants, MPER-ST01 and MPER-ST02, were identified in searches with gp41 residues 659-683 and yielded predicted Cα-RMSDs of 1.34 and 1.25 Å to the gp41 template, respectively (Table 1). Similarity of epitope-matching regions was particularly high for the primary 10E8 contact region within the C-terminal helix, yielding Cα-RMSDs of 1.28 and 0.80 Å (with the full epitope used for superposition), respectively. The third transplant recognized by antibody 10E8, MPER-ST03, was identified in searches with the more limited MPER epitope (gp41 residues 664–683) (Table 1).

MPER-supersite transplants recognized well by antibody 10E8 were next tested for recognition by MPER-specific antibodies from other donors, including antibodies 4E10 and CH12, whose epitopes, like that of 10E8, are located within the C-terminal portion of the MPER [31,36] [Fig. 2d]. Three of the MPER-supersite transplants, MPER-ST01-03, showed recognition to both 10E8 and 4E10, but binding to 4E10 was noticeably weaker than to 10E8 and no recognition to CH12 was observed. In contrast, the MPER as a free peptide is known to bind all MPER-directed broadly neutralizing antibodies with high affinity [33,36,39].

V1V2-supersite transplants

Although variable regions 1 and 2 (V1V2) of the HIV-1 gp120 envelope glycoprotein are among the most sequence variable regions of the HIV-1 viral spike, V1V2 can be recognized by a number of glycopeptide-directed broadly neutralizing antibodies such as PG9, PG16, CH01-04 and GT141–145, from donors IAVI 24, CHAVI 0219 and IAVI 84, respectively [40–42] (Fig. 3a). One particular N-linked glycan at position 160 (HXN2 numbering) defines specificity for all these antibodies, with a second glycan at residue 156 or 173 (depending on isolate) also of importance. The structure of the V1V2 domain in complex with antibody PG9 has been determined for two clade C strains (CAP45 and ZM109) to 2.19 and 1.80 Å, respectively, delineating atomic details of its glycopeptidic epitope [43]. These structures reveal that V1V2 adopts a Greek key motif with strands B and C harboring two PG9-interacting glycans. Similar results were also seen in the structure of V1V2 in complex with PG16, which is closely related to PG9, although the specific glycan requirements differed [44]. The structure of PG9 bound to a soluble gp140 trimer revealed an asymmetric recognition suggesting that potential quaternary interactions may account for the preference of viral spikes over monomeric gp120s for PG9 [45], and the recent structures of the BG505 SOSIP trimer confirmed atomic-level details for a quaternary V1V2 epitope to be spatially in close proximity to the trimeric axis of the viral spike [7,8]. Nonetheless,
Supersite Transplants

A. MPER supersite

B. Clade | Strain | 659 | 664 | 683
---|---|---|---|---
A | B0505 | NEQDLLALDKWASLWNWFDSINWLWYIK | | |
B | JRFL | NEQELLELDKWSLWNWFDSITKWLWYIK | | |
C | ZA012 | NEKDLLALDSWKLWNNWFDTNWLWYIK | MPER | NEQELLELDKWSLWNWFDSITNWLWYIR |

C. Expression

D. Donor Antibody | N152 | n.d. | CAP 206 | n.d.
---|---|---|---|---
MPER-ST01.1-5 | 10E8 | 4E10 | CH12 | 2F5
MPER-ST02.1-4 | +++ | - | - | -
MPER-ST03 | +++ | + | - | -

+++: 10<K<20 nM, ++: 20<K<80 nM, +: 80<K<100 nM, -: no observable binding, n.d.: not determined, mixture of donor cells used.

PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e99881
PG9 has sufficient affinity to monomeric full length V1V2 scaffolds to form stable complexes, with the primary interaction mediated through a glycopeptide epitope from strands B and C of a single gp120 protomer [43].

We tested whether the transplantation of less than the full trimeric V1V2 – perhaps as little as monomeric strands B and C – might allow for a site transplant with antigenic properties comparable to the entire V1V2 (Fig 2b). By using a structural alignment-based scaffolding algorithm, four design “ideas” were explored by matching (i) strands B and C (residues 154–177) to small structurally characterized peptides; (ii) strands B and C to surface-exposed β-hairpin regions; (iii) entire Greek key motif (residues 126–196) comprising four strands to surface-exposed patches; and (iv) an extended stem of the B and C strand termini to similar regions in proteins that can be used as a base to graft strands B and C. A search of the protein structure database identified 33 scaffolds as candidates for site transplantation (Table 2), and 67 supersite transplants consisting of strands B and C from V1V2 were designed with up to 3 variants per individual scaffold (Table S2 in File S1).

All 67 supersite transplants were expressed in HEK293 GtuT- cells in a 96-well microplate and expression levels were quantitated by bio-layer interferometry using anti-penta-his biosensors. Four scaffolded V1V2 proteins with high expression level, 1J08_cap45, 1J08_ZM109, 1FD6_Cap45 and 1FD6_ZM109 [43], were used as controls in the expression assays with a full length gp120 lacking a his-tag as a negative control. Overall, the expression level of the 67 supersite transplants was lower than the four scaffolded V1V2 proteins by several-fold; however, several site transplants showed comparable expression levels (Fig 3c, upper panel). The transplants were further examined for PG9 binding via ELISA with Nπ2+−coated plates. Although most of the proteins showed negligible binding to PG9, epitope-scaffolds derived from 2ZJR [46], 2VXS [47], 1VH8 [48], 3DDC [49] and 1X3E [50] exhibited similar PG9 binding reactivity (by OD450) with respect to the four scaffolded full length V1V2 domains (Fig 3c, lower panel), suggesting that the PG9-bound epitope conformation was properly presented in these scaffolds while employing only strands B and C from the V1V2 domain.

In addition to PG9 binding, all supersite transplants were tested for binding to broadly neutralizing V1V2-directed antibodies from other donors, such as PGT142 and PGT145 (donor IAV84) and CH01 and CH04 (donor CHAVI 0219) to validate appropriate site transplantation (Fig S2). ELISA results reveal that (1) whereas the scaffolded V1V2 proteins used in the crystallization of PG9 [43] only bound to PG9, two supersite transplants (V1V2-ST01 and V1V2-ST04) that bound to PG9 were also reactive to other V1V2-directed neutralizing antibodies (Fig 3d); and (2) although the same minimal epitope was presented by each scaffold, specific V1V2-directed antibodies bound differentially depending upon the scaffolding context, with PGT142 showing the broadest recognition. Despite ELISA-positive binding, none of these transplants retained the nanomolar affinity of the trimeric V1V2 “cap” to broadly neutralizing V1V2-directed antibodies, indicating a failure of these transplants to recapitulate the antigenicity of the target supersite. Likely this failure relates to the quaternary requirements of most V1V2-directed antibodies, and the fact that only a monomeric V1V2 was transplanted in the supersite transplants described here.

Glycan V3-supersite transplants

A glycosylated conserved portion of the variable region 3, termed “glycan V3” on HIV-1 gp120, is another vaccine target of importance (reviewed in [24]) (Fig 4a); notably, the glycan V3 supersite is recognized by the most common broadly neutralizing antibodies elicited during the first two to three years of infection. A series of human antibodies, represented by 2G12, PGT121–123, 10–1074, PGT125–131, PGT135–137, and VRC24 have been isolated with glycan V3-directed specificity [42,51–53]. Previously, a truncated V3 region comprising a “mini-V3” [54] of 3 N-linked glycans and ~25 amino acids was developed by Stanford, Wilson and colleagues in the context of an engineered gp120 outer domain (cODmV3) that bound the PGT128 antibody, and the structure of the complex was reported at a resolution of 3.25 Å (Fig 4b). The crystal structure revealed that PGT128 interacts with two conserved glycans at positions 332 and 301 and with the C-terminal region of the V3 loop, and that a mannoseseN-linked glycan was critical at position 332 [54]. Based on the structure, we hypothesized that a protein with a surface-exposed β-hairpin that was structurally similar to the mini-V3 would be a suitable acceptor scaffold for the entire glycan V3 supersite of vulnerability. With the structural alignment-based algorithm, two stem regions of the V3 loop were used as templates to search for scaffolds with: (1) number of residues in the range of 40–80, (2) Cα RMSD lower than 1.5 Å, and (3) a clash score near zero. Twenty non-homologous proteins were selected (Table 3), and the mini-V3 was grafted onto each scaffold (Table S3 in File S1).

Similar to the screening of V1V2-supersite transplants, all 20 glycan V3-supersite transplants were expressed in HEK293T cells in the 96-well microplate and in the presence of 10 μg/ml fitanesine to ensure uniform mannoseseN-linked glycosylation. A 2F5 scaffold, 2F5-ES2 [17], with high expression level was used as a control in expression assays (Fig 4c, top panel). The binding of the glycan V3-supersite transplants to PGT128 was assessed by ELISA. 11 of these 20 transplants bound to PGT128 with OD450 ranging from 1.0 to 3.5 (Fig 4c, bottom panel, Fig S3) (glycan V3-ST01-ST11). We also tested binding of these 11 transplants to glycan V3-directed antibodies from other donors. Remarkably, seven of the glycan V3-site transplants showed tight binding to glycan V3-directed broadly neutralizing antibodies from at least three other donors (Fig 4d).

Structural and glycan specificity of glycan V3-supersite transplants

Because the seven glycan V3-supersite transplants that we identified through our combined computational-experimental strategy differed so substantially in their antigenic behavior from the more than 100 other transplants in their ability to bind broadly neutralizing antibodies from multiple donors, we sought to further characterize the structural and antigenic integrity of these supersite transplants and their recognizing antibodies.
Table 1. Twenty-one acceptor proteins identified for MPER-supersite transplantation by using a TMalign-based search method.\(^a\)

| Acceptor (PDB ID) | MPER-supersite transplant | Chain | SS% (H/S) | \(N_{\text{res}}\) | \(N_{\text{ali}}\) | \(C_{\text{r}}\)-RMSD | TM-score | SA ratio | Clash | \(N_{\text{var}}\) |
|-------------------|----------------------------|-------|-----------|----------------|----------------|-----------------|----------|---------|-------|----------|
| 2CW9              | -                          | A     | 41.2/32.4 | 182           | 28             | 1.43            | 0.237    | 0.630   | 3.841 | 4        |
| 3O8I              | A                          | 1     | 18.9/37.0 | 127           | 26             | 1.34            | 0.300    | 0.657   | 1.321 | 5        |
| 2UXE              | -                          | A     | 69.3/0.0  | 114           | 26             | 1.06            | 0.332    | 0.550   | 4.068 | 5        |
| 1ONQ              | -                          | A     | 24.5/43.1 | 274           | 26             | 1.29            | 0.161    | 0.508   | 2.868 | 5        |
| 3MHS              | 2                          | B     | 82.4/0.0  | 91            | 26             | 1.25            | 0.380    | 0.592   | 0.000 | 4        |
| 1OCK              | -                          | A     | 38.3/15.0 | 412           | 26             | 1.05            | 0.115    | 0.527   | 6.285 | 4        |
| 3AGJ              | 3                          | A     | 18.8/32.4 | 432           | 19             | 1.40            | 0.080    | 0.505   | 0.000 | 1        |
| 2NN4              | -                          | A     | 69.0/0.0  | 62            | 19             | 1.73            | 0.386    | 0.526   | 0.000 | 2        |
| 3DMA              | -                          | A     | 39.4/17.6 | 340           | 19             | 1.40            | 0.101    | 0.503   | 0.000 | 1        |
| 3KZ5              | -                          | A     | 25.5/38.3 | 47            | 19             | 1.21            | 0.455    | 0.663   | 0.000 | 2        |
| 2QRW              | -                          | A     | 67.5/0.0  | 126           | 19             | 1.53            | 0.229    | 0.529   | 1.199 | 1        |
| 3GJ0              | -                          | A     | 29.5/24.6 | 207           | 19             | 1.50            | 0.152    | 0.521   | 1.396 | 1        |
| 3KVH              | -                          | A     | 31.8/30.2 | 192           | 20             | 1.76            | 0.168    | 0.504   | 2.516 | 1        |
| 3IX3              | -                          | A     | 47.9/16.6 | 163           | 19             | 1.83            | 0.178    | 0.457   | 2.526 | 1        |
| 1UB4              | -                          | A     | 25.2/34.0 | 103           | 19             | 1.71            | 0.253    | 0.499   | 0.000 | 2        |
| 1U6Z              | -                          | A     | 45.2/15.7 | 498           | 20             | 0.89            | 0.076    | 0.408   | 2.441 | 1        |
| 2CJW              | -                          | A     | 39.3/22.5 | 178           | 19             | 1.64            | 0.168    | 0.643   | 1.120 | 1        |
| 2D4U              | -                          | A     | 85.0/0.0  | 167           | 19             | 1.32            | 0.185    | 0.504   | 0.000 | 1        |
| 3AG3              | -                          | H     | 54.0/0.0  | 79            | 20             | 1.31            | 0.345    | 0.618   | 0.000 | 2        |
| 3HW5              | -                          | A     | 50.8/13.0 | 177           | 19             | 1.37            | 0.174    | 0.406   | 2.312 | 1        |
| 3IUO              | -                          | A     | 70.9/0.0  | 110           | 21             | 1.83            | 0.274    | 0.538   | 2.398 | 2        |

\(^a\)Listed items include supersite index, PDB identifier, chain name, percent secondary structure composition (helix/sheet), number of residues in the supersite, number of residues aligned to the epitope, \(C_{\text{r}}\) RMSD of aligned residues, TM-score from TMalign output, solvent accessibility ratio between the epitope-matching region in the transplant context versus the epitope alone, transplant-antibody clash score, and number of variants designed based on each transplant.

doi:10.1371/journal.pone.0099881.t001
Supersite Transplants

Figure 3. V1V2-supersite transplants. Supersite transplants were designed to maintain the PG9-interacting strands B and C in the antibody bound conformation. Four design ideas were explored for transplanting the B and C strands: matching (i) strands B and C (residues 154–177) to small structurally characterized peptides; (ii) strands B and C to surface-exposed β-hairpin regions; (iii) the entire Greek key motif (residues 126–196) comprising four strands to surface-exposed patches; and (iv) extending the base of the B and C strands (A) V1V2-supersite location on viral spike. (B)
We first explored whether the recognizing antibodies could bind to mini-V3 in a flexible, non-scaffolded context. We linked mini-V3 comprising the 2 sites of N-linked glycosylation and ~25 amino acids with no scaffold, but only a flexible linker, to the constant region (Fc) of an immunoglobulin to create “mini-V3–Fc”. We test the recognition of mini-V3–Fc by a panel consisting of 15 broadly neutralizing antibodies from 5 donors (Table 4). None of the broadly neutralizing antibodies directed with glycan V3-specificity bound to the mini-V3–Fc construct (Table 4). A substantial proportion of the broadly neutralizing antibodies did, however, show nM affinity to multiple glycan V3-supersite transplants, though not to other regions of Env (Table 4). These results indicate that recognition of the transplanted mini-V3 was dependent on the heterologous protein scaffold providing an appropriate structural context.

Next we analyzed the glycan requirements of recognizing antibodies for the glycan V3-supersite transplants. A mannosε5,N- linked glycan is known to be required at residue N332 of HIV-1 V3-site transplants were expressed in the presence of kifunensine (which ensures mannose9,-linked glycan is known to be required at residue N332 of HIV-1). We first explored whether the recognizing antibodies could bind to the mini-V3-Fc construct (Table 4). A substantial proportion of the broadly neutralizing antibodies did, however, show nM affinity to multiple glycan V3-supersite transplants, though not to other regions of Env (Table 4). These results indicate that recognition of the transplanted mini-V3 was dependent on the heterologous protein scaffold providing an appropriate structural context.

Next we analyzed the glycan requirements of recognizing antibodies for the glycan V3-supersite transplants. A mannosε5,N-linked glycan is known to be required at residue N332 of HIV-1 for recognition by broadly neutralizing antibodies like PGT122, PGT128, PGT135 and 2G12 [42,55,56]. Only when the glycan V3-site transplants were expressed in the presence of kifunensine (which ensures mannosε5,N-linked glycosylation) but not in the presence of swansonine (which allows glycan processing to produce mannosε5,N-linked glycans and hybrid biantennary sugars) did the broadly neutralizing antibodies PGT128, 10–1074 and 2G12 recognize the seven glycan V3-supersite transplants (Fig. 5). These results indicate that recognition by the broadly neutralizing antibodies for the glycan V3-supersite transplants retained the same dependence for a particular type of N-linked glycosylation as with recognition of native Env.

Mini-V3 comprises essential components of glycan V3 supersite

To gain insight into the ability of the transplanted mini-V3 to recapitulate both the glycan-requirements and the antigenic recognition of the glycan V3 supersite, we analyzed the structural composition of epitopes recognized by glycan V3-targeting broadly neutralizing antibodies (Fig. 6a,b). Crystal structures of Env complexes have been determined with glycan V3-directed broadly neutralizing antibodies [58]. Crystal structures of Env complexes have been determined with glycan V3-directed broadly neutralizing antibodies [58]. We quantified the relative ability of somatic variants from donors from which multiple broadly neutralizing antibodies have been isolated to recognize the glycan V3-supersite transplants. Antibodies from donor IAVI 36 (PGT125–131) showed the most comprehensive recognition: for the best 7 transplants, 29 tested combinations showed nM affinity out of a possible 35. For donor IAVI 39 (PGT121–123, 10–1074 and 10–996) and with the best 7 transplants, 14 tested combinations showed nM affinity out of a possible 35. For donor IAVI 17 (PGT135–137), for the best 7 transplants, only 1 tested combination showed µM affinity out of a possible 21. Similar ratios of recognition were observed for all 11 transplants with positive ELISA recognition of PGT128. Notably, these ratios correlated with the percentage of the epitope contributed by the mini-V3 (Fig. 6E). Altogether these results indicate that the ability of the glycan V3-site transplants to recapitulate recognition by template broadly neutralizing antibodies correlates with the transplanted portion of the epitope. Despite retaining less than 50% of the supersite, glycan V3 transplants may still have nM affinity to the target antibodies.

Glycan V3-supersite transplants in nanoparticle contexts

Finally we asked how the placements of the transplants into nanoparticle contexts might alter the recognition by the target antibodies. Because nanoparticles have shown utility in enhancing both antigenicity and immunogenicity [57] and because the small, rigid proteins identified as suitable acceptor scaffolds for the glycan V3-supersite of vulnerability might be also suitable for presentation on a virus-like particle (VLP) or other multivalent platforms [58], we transplanted the glycan V3-supersites into the ferritin nanoparticle context (Table S4 in File S1). The ferritin from H. pylori has octahedral symmetry and assembles into a nanoparticle of 24 subunits, arrayed as 8 trimers, and placement of influenza hemagglutinin in this context was shown to enhance immunogenicity by over 10-fold [57]. When tested by surface plasmon resonance, the glycan V3-supersite transplants in the ferritin nanoparticle context retained their ability to bind to broadly neutralizing antibodies. Notably, the off-rate of the interaction with antibodies was reduced in the ferritin nanoparticle context relative to the native immunogen (Fig. 7a, Table 5). We also analyzed how the nanoparticle context affected recognition to the multiple somatic variants from IAVI donors 17, 36 and 39. The results showed that the presentation of glycan V3 site in nanoparticle context did not change the overall antigenic profile although it did improve their apparent affinity (Fig. 7b). Together, these results indicate that the antigenicity of mini-V3 could be enhanced by structure-based means of optimization, in this case, by nanoparticle oligomerization.

Discussion

HIV-1 and other pathogens employ multiple overlapping mechanisms to evade the immune response. One potential strategy to overcome these immune-evading mechanisms is to extract a particular viral epitope recognized by a potent neutralizing antibody and to present it in a scaffolded context that retains the antigenic character of the epitope, but separates it from the
Table 2. Thirty-three protein scaffolds identified for PG9 epitope transplantation using a TMalign-based search method.\(^a\)

| Acceptor (PDB ID) | V1V2-supersite transplant | Chain | SS% (H/S) | \(N_{\text{res}}\) | \(N_{\text{ali}}\) | C\(_{\text{a}}\)-RMSD | TM-score | SA ratio | Clash | \(N_{\text{var}}\) |
|-------------------|---------------------------|-------|-----------|----------------|----------------|-----------------|-----------|---------|-------|-----------|
| 2JNI              | - A                        | 0.0/76.2 | 21         | 21              | 0.94           | 0.385           | 0.881     | 0       | 2     |           |
| 3BW1              | - A                        | 6.1/51.2 | 86         | 22              | 1.12           | 0.34            | 0.76      | 0       | 3     |           |
| 2QLD              | - A                        | 10.5/40.9 | 171     | 24              | 0.93           | 0.233           | 0.749     | 3       | 169    | 3         |
| 2ZJR              | - Q                        | 20.4/17.2 | 93         | 22              | 1.76           | 0.298           | 0.711     | 1.342   | 2     |           |
| 2BYK              | - A                        | 31.5/41.6 | 89         | 22              | 1.32           | 0.326           | 0.697     | 0       | 2     |           |
| 2VQE              | - Q                        | 11.5/51.9 | 104        | 24              | 1.64           | 0.303           | 0.694     | 10.274  | 3     |           |
| 1APY              | - B                        | 20.6/33.3 | 141        | 22              | 1.61           | 0.227           | 0.669     | 3.946   | 1     |           |
| 3DDC              | - B                        | 24.1/39.1 | 133        | 23              | 1.77           | 0.24            | 0.668     | 4.339   | 1     |           |
| 3HRD              | - D                        | 31.9/16.2 | 160        | 22              | 1.94           | 0.197           | 0.65      | 0       | 2     |           |
| 1YN3              | - A                        | 22.4/42.9 | 98         | 23              | 1.84           | 0.291           | 0.642     | 1.184   | 1     |           |
| 1WOC              | - A                        | 0.0/68.7  | 99         | 22              | 1.49           | 0.304           | 0.635     | 0       | 3     |           |
| 2ZPM              | - A                        | 16.3/36.0 | 86         | 22              | 1.3            | 0.328           | 0.616     | 0       | 1     |           |
| 1LFQ              | - A                        | 17.2/33.3 | 87         | 24              | 2.13           | 0.319           | 0.693     | 3.157   | 1     |           |
| 1T3Q              | - A                        | 31.5/15.4 | 162        | 22              | 2.18           | 0.196           | 0.666     | 1.066   | 1     |           |
| 2IAB              | - A                        | 20.9/38.6 | 153        | 24              | 2.07           | 0.218           | 0.662     | 3.823   | 1     |           |
| 3NEC              | - A                        | 25.3/41.4 | 162        | 22              | 2.52           | 0.175           | 0.66      | 0       | 1     |           |
| 2VXS              | - A                        | 4.7/47.7  | 86         | 24              | 2.44           | 0.293           | 0.658     | 0       | 1     |           |
| 1NF3              | - C                        | 12.2/38.2 | 123        | 22              | 2.03           | 0.234           | 0.646     | 0       | 1     |           |
| 2HQL              | - A                        | 10.6/57.7 | 104        | 24              | 2.35           | 0.269           | 0.613     | 52.008  | 3     |           |
| 3FEV              | - A                        | 0.0/56.9  | 65         | 23              | 2.27           | 0.332           | 0.607     | 6.484   | 3     |           |
| 1GVP              | - A                        | 0.0/46.0  | 87         | 39              | 2.9            | 0.412           | 0.599     | 0       | 1     |           |
| 3EN2              | - A                        | 66.6/64.8 | 91         | 39              | 3.29           | 0.359           | 0.525     | 0       | 3     |           |
| 1GG3              | - A                        | 33.0/17.9 | 279        | 38              | 3              | 0.186           | 0.524     | 2.127   | 1     |           |
| 2AR5              | - A                        | 35.9/20.5 | 117        | 40              | 2.86           | 0.36            | 0.517     | 9.193   | 1     |           |
| 2F7S              | - A                        | 34.6/25.7 | 179        | 26              | 1.42           | 0.223           | 0.784     | 2.127   | 3     |           |
| 3HM2              | - A                        | 31.0/28.1 | 171        | 27              | 1.18           | 0.249           | 0.677     | 4.71    | 3     |           |
| 1D3B              | - B                        | 0.0/56.8  | 81         | 25              | 1.94           | 0.347           | 0.665     | 0       | 3     |           |
| 1L3I              | - A                        | 31.7/29.6 | 186        | 27              | 1.53           | 0.221           | 0.624     | 2.127   | 3     |           |
| 1VH8              | 4 A                        | 29.4/36.6 | 153        | 27              | 2.49           | 0.234           | 0.735     | 2.127   | 3     |           |
| 1X3E              | 5 A                        | 8.2/50.0  | 110        | 26              | 2.35           | 0.269           | 0.619     | 0       | 3     |           |
| 3L1E              | - A                        | 0.0/50.0  | 105        | 27              | 2.64           | 0.255           | 0.616     | 0       | 2     |           |
| 1DHN              | - A                        | 32.2/33.1 | 121        | 26              | 2.26           | 0.272           | 0.61      | 2.127   | 2     |           |
| 1BM9              | - A                        | 54.3/11.7 | 120        | 26              | 2.42           | 0.279           | 0.605     | 27.675  | 3     |           |

\(^a\)Listed items include scaffold index, PDB identifier, chain name, percent secondary structure composition (helix/sheet), number of residues in the scaffold structure, number of residues aligned to the epitope, \(C_{\text{a}}\)-RMSD of aligned residues, TM-score from TMalign output, solvent accessibility ratio between the epitope-matching region in the scaffold context versus the epitope alone, scaffold-antibody clash score, and number of variants designed based on each scaffold.

doi:10.1371/journal.pone.0099881.t002
immune-evading mechanisms that hinder the elicitation of effective neutralizing antibodies in the native viral context.

There are now multiple examples of epitope-focused vaccine design in both sequence and various structure-based contexts. In 2006, Chakraborty and colleagues showed that transplantation of the V3 region from HIV-1 gp120 into a thioredoxin scaffold could elicit neutralizing antibodies to the MN strain of HIV-1, though not to Tier 2 neutralization-resistance strains like JR-FL or BAL [59], while later studies showed that a constrained V3 peptide was a more optimal immunogen than a linear one [60]. In 2010, Ofek and colleagues showed that scaffolding of the MPER epitope for the 2F5 antibody into various acceptor scaffolds allowed for structure-specific elicitation, with elicited antibodies able to induce the scaffolded β-hairpin in flexible MPER peptides, which otherwise assume helical conformations [17]. In 2010, Totrov and colleagues showed that placement of the V3 region from HIV-1 gp120 into a multivalent cholera toxin scaffold could, after DNA-prime/protein boost, elicit an immune response that

Figure 4. Glycan V3-supersite transplants. Supersite transplants were designed to maintain the mini-V3 in its PG128-bound conformation. (A) Location of glycan V3 supersite on HIV-1 viral spike. (B) Sequence alignment of the V3 loop from clades A, B and C with potential glycosylation positions marked above and V3 region-structural elements marked below. The transplanted glycan V3-supersite sequence was shown with the mini-V3 highlighted in red. (C) (top) 96-well expression of 20 glycan V3-supersite transplants and Ni-Sensor Octet quantitation of expression levels. 2F5-E52 was used as expression control. (bottom) ELISA of PGT128 antibody binding of the expressed glycan V3 transplants. 11 of the 20 glycan V3 transplants showed substantial interaction with PGT128 (red). (D) Glycan V3-supersite transplants which showed significant PGT128 binding were tested for binding to additional glycan V3-directed antibodies from different donors.

doi:10.1371/journal.pone.0099881.g004
Table 3. Twenty protein scaffolds identified for glycan V3-supersite transplantation by using a TMalign-based search method.\(^a\)

| Acceptor (PDB ID) | Gycan V3-supersite transplant | Chain | SS% (H/S) | N\(_{\text{ss}}\) | N\(_{\text{ali}}\) | C\(_r\)-RMSD | TM-score | SA ratio | Clash | N\(_{\text{var}}\) |
|-------------------|-------------------------------|-------|-----------|----------------|----------------|-------------|-----------|---------|-------|---------|
| 3I8Z              | 1                             | A     | 8.0/44.0  | 50             | 11             | 1.16        | 0.237     | 0.567   | 0.000 | 1       |
| 3HSH              | 2                             | A     | 12.5/32.1 | 56             | 12             | 1.48        | 0.233     | 0.492   | 0.000 | 1       |
| 1RH6              | -                             | A     | 27.8/25.9 | 55             | 12             | 1.26        | 0.252     | 0.544   | 0.000 | 1       |
| 3C4S              | -                             | A     | 0.0/56.1  | 57             | 12             | 1.38        | 0.239     | 0.431   | 0.000 | 1       |
| 3LWE              | 3                             | A     | 31.1/36.1 | 61             | 12             | 1.38        | 0.237     | 0.565   | 0.000 | 1       |
| 1M80              | 4                             | A     | 21.3/42.6 | 61             | 12             | 0.91        | 0.271     | 0.354   | 0.000 | 1       |
| 2CC6              | -                             | A     | 23.4/51.6 | 64             | 12             | 1.42        | 0.215     | 0.434   | 0.000 | 1       |
| 1NXB              | 5                             | A     | 0.0/41.9  | 62             | 11             | 1.33        | 0.220     | 0.495   | 0.000 | 1       |
| 1EAY              | -                             | C     | 29.9/25.4 | 67             | 12             | 1.21        | 0.221     | 0.457   | 0.000 | 1       |
| 2VQC              | -                             | A     | 57.1/17.1 | 70             | 12             | 1.38        | 0.222     | 0.480   | 0.000 | 1       |
| 1BF               | 6                             | A     | 8.5/59.2  | 71             | 12             | 1.46        | 0.224     | 0.546   | 0.000 | 1       |
| 1DUR              | 7                             | A     | 9.1/18.2  | 55             | 11             | 0.99        | 0.244     | 0.416   | 0.000 | 1       |
| 1FR3              | 8                             | A     | 10.4/50.7 | 67             | 10             | 0.52        | 0.238     | 0.522   | 0.000 | 1       |
| 1DP7              | -                             | P     | 42.1/31.6 | 76             | 10             | 1.35        | 0.175     | 0.611   | 0.000 | 1       |
| 1GUT              | 9                             | A     | 10.4/46.3 | 67             | 11             | 0.85        | 0.239     | 0.476   | 0.000 | 1       |
| 2AST              | -                             | C     | 15.9/33.3 | 69             | 12             | 0.57        | 0.275     | 0.576   | 0.000 | 1       |
| 1WHZ              | -                             | A     | 37.1/22.9 | 70             | 12             | 1.30        | 0.225     | 0.511   | 0.000 | 1       |
| 2P09              | 10                            | A     | 36.2/20.3 | 69             | 12             | 1.25        | 0.226     | 0.436   | 0.000 | 1       |
| 3CA7              | 11                            | A     | 12.0/36.0 | 50             | 11             | 1.04        | 0.250     | 0.511   | 0.000 | 1       |
| 3FRY              | -                             | A     | 27.4/12.3 | 73             | 12             | 1.43        | 0.208     | 0.549   | 0.000 | 1       |

\(^a\)Listed items include scaffold index, PDB identifier, chain name, percent secondary structure composition (helix-sheet), number of residues in the scaffold structure, number of residues aligned to the epitope, C\(_r\)-RMSD of aligned residues, TM-score from TMalign output, solvent accessibility ratio between the epitope-matching region in the scaffold context versus the epitope alone, scaffold-antibody clash score, and number of variants designed based on each scaffold.

doi:10.1371/journal.pone.0099881.t003
Table 4. Binding affinity of glycan V3-supersite transplants to antibodies isolated from diverse donors.

| Epitope | Glycan V3 | V3 MPER | V1V2 | CD4BS |
|---------|-----------|---------|------|-------|
| IAVI    | 36        | IAVI    | 39   | IAVI  |
| 24      | NIAID45   | IA VI   | 17   | NA    |

| Antibody | PGT125 | PGT126 | PGT127 | PGT128 | PGT129 | PGT131 | PGT132 | PGT133 | PGT134 | PGT135 | PGT136 | PGT137 | PGT138 | PGT139 |
|----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 10^-4    | 55     | 70     | 35     | 56     | 46     | 27     | 43     | 50     | 56     | 46     | 27     | 43     | 50     |
| 10^-9    | 100    | 70     | 35     | 56     | 46     | 27     | 43     | 50     | 46     | 27     | 43     | 50     |
| 10^-12   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   |

*: NB: no binding detected, NA: not available.

Table 4: Binding affinity of glycan V3-supersite transplants to antibodies isolated from diverse donors.

The table presents data on the binding affinity of glycan V3-supersite transplants to antibodies isolated from diverse donors. The transplants are listed under the Epitope column, with details such as V3 MPER, V1V2, and CD4BS. The antibodies tested are listed under the Antibody column, including PGT125, PGT126, PGT127, etc. The binding affinities are expressed in units of 10^-4, 10^-9, and 10^-12, indicating the concentration range for detection.

As mentioned in the article, the glycan V3-supersite transplants were able to replicate the antigenicity of the glycans V3 and V1V2, suggesting that the antigenic mimicry against antibodies from a specific donor correlated with the portion of the transplanted supersite recognized by antibodies from that specific donor.

The table highlights that only a portion of the glycan V3 supersite was transplanted, and the degree of antigenic mimicry against antibodies from a specific donor correlated with the portion of the transplanted supersite recognized by antibodies from that specific donor. This is supported by a design that incorporates the transplantation of a larger portion of the supersite may have greater antigenic breadth. In this regard, it should be noted that the glycan V3-supersite is one of the most promiscuously recognized of the HIV-1 Env supersites of vulnerability. Antibodies that recognize this supersite range from PGT122, which binds a glycopeptide V1-V3 spanning epitope, to PGT135, which binds a glycopeptide V3-V4 spanning epitope, and to 2G12, which binds a glycan-only epitope [64]. It remains to be seen whether transplants comprising greater
portions of the glycan V3 supersite would make more effective probes or immunogens; we note in this context that it remains to be shown whether the glycan V3-supersite transplants described here can elicit effective HIV-1-neutralizing antibodies – either alone, as cocktails, or as components in prime/boost regimens. Nevertheless, the structural and antigenic analyses described here, along with the successful oligomerization of the glycan V3-supersite transplants in the ferritin nanoparticle context, do demonstrate that supersite transplants with antigenic mimicry of the template supersite can be achieved through transplantation of only a portion of the recognized supersite. Overall, the design framework and described glycan V3-supersite transplants provide both conceptual context and initial immunogens for a supersite-focused vaccine effort.

Figure 5. Glycosylation of glycan V3-supersite transplants and antibody reactivity. SPR sensorgrams showed binding of PGT128 (donor 39) and 10–1074 (donor 39) to the 7 glycan V3 transplants expressed in 293F cells in the presence of glycosylation inhibitors kifunensine (solid line) or swainsonine (dashed line). doi:10.1371/journal.pone.0099881.g005

Figure 6. Contribution of the mini-V3 region to the epitopes of antibodies targeting the glycan V3 supersite. (A) (left) HIV-1 viral spike with mini-V3 region shown in red. (middle and right) Different views of binding modes for glycan V3-targeting antibodies PGT122, PGT128 and PGT135. (B) Surface representation of HIV-1 gp120 with glycans involved in antibody binding shown in sticks. The antibody epitope from the mini-V3 region were colored red and epitope from non-glycan V3 regions were colored cyan. (C) Sequence alignment of the glycan V3 region with antibody interacting residues highlighted in red. The mini-V3 was boxed and the residue numbers above marked the potential glycosylation sites. (D) Comparison of epitope surface area contributed by the glycan V3 region and other regions for antibodies PGT122, PGT128 and PGT135. (E) Percentage of epitope contribution by transplanted glycan V3 site correlated with the reactivity of the glycan V3-supersite transplants to somatic variants of template antibodies. doi:10.1371/journal.pone.0099881.g006
Materials and Methods

Protein structure database

A protein structure database was compiled for the scaffolding search. To ensure both coverage and diversity of the obtained scaffolds, the PISCES [65] server was used to generate a representative, non-homologous set of Protein Databank (PDB) entries at the 90% identity level, with a resolution cutoff of 3.0 Å, and an R-factor cutoff of 1.0. As of October 29, 2010, the PISCES server yielded an annotated list of 19,500 peptide chains after screening with sequence similarity and structure quality filters. All protein chains with only Cα atoms were marked; duplicate chains were eliminated from each entry in the database compilation; modified amino acids were identified from a look-up table of pre-defined types and renamed accordingly with the modified groups removed; insertions were renumbered so that their residue numbers were in ascending order in the resulting PDB file.

Scaffolding/transplantation for vaccine design

The scaffolding/transplantation-based vaccine design (Fig. 1) consists of identification of supersites of HIV-1 vulnerability to broadly neutralizing antibodies on the pathogen, structural characterization of antibody-epitope interactions, structure-based computational design of supersite transplants, and antigenic and structural analysis of the supersite transplants. The computational scaffolding/transplantation procedure is essential to this vaccine strategy and contains four steps.

In Step 1, an exhaustive search is performed to find scaffold proteins suitable for supersite transplantation. In our study, a scaffolding algorithm based on structural alignment [26] was implemented and tested. The scaffolding search results in a list of PDB entries with key parameters calculated for each entry, including protein size (number of residues), matching criteria (Cα RMSD and number of residues matched), template-epitope exposure in the scaffold context, and a simple scaffold-antibody clash score (sum of $r^2$ for all heavy-atom contacts within 1 Å).

Desired scaffolds are then selected based on these parameters.

In Step 2, two grafting approaches may be used to produce a supersite transplant model. If all template-antibody epitope residues can find matches in the scaffold protein, ‘side-chain grafting’ is sufficient. However, when the template antibody-epitope cannot be matched to a scaffold region residue by residue, ‘backbone grafting’ has to be utilized to generate the atomic model. In such cases, template antibody-epitope residues – both backbone and side chain atoms – are grafted onto target protein by superposition of selected anchoring points, e.g. N- and C-terminal residues of the epitope loop. The supersite-transplant models may be further relaxed by energy minimization.

In Step 3, supersite transplant models are evaluated using empirical scoring functions and statistical potentials, which have been applied to evaluate homology models and large structure ensemble generated by MD simulation [66]. Briefly, the tabulated soft-core van der Waals (vdW) function can be used to detect steric clashes, while the statistical potential DFIRE [29] is more sensitive to unfavorable side-chain contacts. High scoring residues (e.g. ≥2

Figure 7. Nanoparticle presentation enhances affinity but not diversity of antigenic recognition of glycan V3-supersite transplants. (A) SPR sensograms showing the binding to template antibodies PGT128 and 10–1074 for glycan V3 ST11 in its native and ferritin nanoparticle forms. (B) Antigenicity profile of glycan V3 ST08-11 in their ferritin nanoparticle forms. doi:10.1371/journal.pone.0099881.g007
DFIRE score) interacting with the grafted supersite may be subjected to visual inspection and further side-chain modeling.

In Step 4, problematic residues are optimized using a side-chain modeling/prediction program that combines a statistical potential (DFIRE), an XYZ side-chain rotamer library [67] and a combinatorial search algorithm named FASTER [68].

### Structural alignment-based scaffolding

We used TM-align [26], a structural alignment algorithm, as core engine for scaffolding search. Compared with other widely used methods [28], TM-align uses a different scoring scheme (termed TM-score [69]) that emphasizes more on global similarity than local deviations, that could affect structure fitting and lead to a large RMSD value. Due to the stochastic nature of the structural alignment algorithm, parameters such as epitope length could have notable effect on the outcome and therefore have been tested in each run to find optimal values. For a multi-segment epitope, different orders of the segments were tried in separate scaffolding runs as the structural alignment algorithm assumes a sequential order of the residues provided in the epitope PDB file. It is also worth noting that each epitope residue is weighted equally in the algorithm and as a result the scaffolds found may be biased towards the larger segment(s) in a multi-segment epitope.

### Construction of plasmids encoding supersite transplants

Sequences for each of the scaffolds from different designs were codon optimized for expression in Homo sapiens, synthesized and cloned into the pJ603 or pVRC8400 mammalian expression vectors (DNA 2.0, CA; Life Technologies, CA). For the 10E8 supersite transplants, Hisx8/Strep or GFP/Hisx8 tags were appended to the C-terminus of the transplants. For the V1V2-supersite transplants, Hisx8/Strep tags were appended to the C-terminus of the transplants. For the glycan V3-supersite transplants, HRV3C cleavage site and Hisx8/Strep tags were appended to the C-terminus of the transplants. To create a flexible, non-scaffolded mini-V3, the sequence EINCTRPNNNTRPGEIIGDIRQAHC-NIS was fused to the Fc portion of human IgG1 with a GG linker. A HRV3C cleavage site was also inserted after the GG linker for cleaving the mini-V3 peptide off the Fc carrier when needed. The plasmids were prepared by standard methods (DNA 2.0, CA, or GeneImmune, MD).

### Transient transfection expression of supersite transplants in 96-well microplates

A 96-well microplate-formatted transient gene expression approach was used to achieve high-throughput expression and screening of various scaffold proteins. HEK 293T cells (Invitrogen, CA) were thawed and incubated with growth medium (High Glucose Dulbecco’s Modified Eagle Medium with 10% Fetal Bovine Serum and 1% streptomycin-penicillin) (Invitrogen, CA) at 37°C, 5% CO2, until the cells reached logarithmic physiological growth. 24 hours prior to DNA-transient transfection, 100 ml of physiologically growing cells was seeded in each well of a 96-well microplate at a density of 2.5 x 10^5 cells/ml in expression medium (High Glucose Dulbecco’s Modified Eagle Medium supplemented with 10% Ultra-Low IgG Fetal Bovine Serum and 1x-Non-Essential Amino Acids) (Invitrogen, CA), and incubated at 37°C, 5% CO2 for 20 hours. Two hours prior to transfection, 100 µl of spent medium from each well was replaced with 60 µl of fresh expression medium.

DNA-TrueFect-Max complexes were used for transfection, and these were prepared by mixing 0.2 µg plasmid DNA in 10 µl of Opti-MEM transfection medium (Invitrogen, CA) with 0.4 µl of

---

**Table 5. Presentation of glycan V3-supersite transplants in a nanoparticle context reduces their apparent rate of dissociation.**

| Glycan V3 Binding to PGT128 | Native | Ferritin | Fold decrease of k_{off} | KD (nM) | k_{on} (M^{-1} s^{-1} x 10^{10}) | k_{off} (s^{-1} x 10^{-10}) |
|-----------------------------|--------|----------|-------------------------|---------|-------------------------------|---------------------------|
| Binding to 10E8             | ST08   | 6.17     | 0.367                   | 1.1     | 4.3                           | 1.2                       |
|                            | ST09   | 11.60    | 0.92                   | 2.5     | 3.6                           | 0.7                       |
|                            | ST10   | 27.0     | 2.8                    | 4.3     | 4.3                           | 1.6                       |
|                            | ST11   | 31.6     | 6.5                    | 4.7     | 4.7                           | 1.8                       |

| Glycan V3 Binding to 10-1074 | Native | Ferritin | Fold decrease of k_{off} | KD (nM) | k_{on} (M^{-1} s^{-1} x 10^{10}) | k_{off} (s^{-1} x 10^{-10}) |
|-----------------------------|--------|----------|-------------------------|---------|-------------------------------|---------------------------|
| Binding to 10E8             | ST08   | 49.8     | 0.81                    | 4.2     | 21.9                          | 2.5                       |
|                            | ST09   | 95.9     | 0.83                    | 2.5     | 2.1                           | 2.4                       |
|                            | ST10   | 27.0     | 0.24                    | 10.5    | 2.3                           | 2.3                       |
|                            | ST11   | 31.6     | 6.5                    | 4.7     | 4.7                           | 1.8                       |

**Table 5.** Presentation of glycan V3-supersite transplants in a nanoparticle context reduces their apparent rate of dissociation.
After 5-time wash with wash buffer, the wells were incubated with PLOS ONE | www.plosone.org 17 July 2014 | Volume 9 | Issue 7 | e99881 m

450 nm. All samples were performed in duplicate.

Expression and purification of antibody IgG and supersite transplant recombinant proteins

For each 1 L expression, 500 µg of supersite transplant plasmid DNA (or 250 µg of each heavy chain and light chain plasmid DNAs) were added to 20 ml of Opti-MEM transfection medium (Invitrogen, CA) and combined with 20 ml of Opti-MEM transfection medium containing 1 ml of TrueFect-Max transfection reagent (United Biosystems, Bethesda, MD). The DNA-TrueFect-Max complexes were incubated for 20 minutes at room temperature before adding to 800 ml of Freestyle 293F cell culture (1.4×10⁶ cells/ml) in a 2-L shaking flask. For expression of the glycans V3-supersite transplant proteins, Freestyle 293F cells were pre-incubated with glycans inhibitor kifunensine (Enzo Life Sciences, NY) at 12.5 mg/L, or swainsonine at 10 mg/L, for 2 hours prior to transfection. The cell culture was returned to suspension incubation for 24 hours at 37°C, 8% CO₂ and 215 rpm, and then fed with 100 ml of enriched CellBoost-5 medium (HyClone, Logan, UT) containing 1 mM valproic acid (SIGMA, St. Louis, MO) (for antibodies) or sodium butyrate (SIGMA, St. Louis, MO) (for supersite transplant proteins) as expression enhancer. The supernatant was harvested 6 days post-transfection by centrifugation and filtered through 0.22 µm filter. The antibody IgG was purified by Protein A affinity column (-Protein A Plus Agarose, Thermo Scientific, Rockford, IL). The supersite transplant proteins were purified by Ni-NTA column (Ni-NTA resin, QIAGEN, Valencia, CA) followed by gel filtration with a Superdex S200 column (GE Healthcare, NJ).

Surface plasmon resonance

Binding affinities of the supersite transplants and their variants to antibodies were assessed by surface plasmon resonance on a Biacore T-200 (GE Healthcare) at 20°C with buffer HBS-EP⁺ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P-20). In general, mouse anti-human Fc antibody was first immobilized onto a CM5 chip at 8000-10000 response units (RU) with standard amine coupling protocol (GE Healthcare). Human anti-HIV antibody IgG were then captured with the immobilized anti-human Fc antibody to 250–500 response units (RUs). Site transplants at 2-fold increasing concentrations were injected over the captured antibody channel and a reference channel without captured IgG at a flow rate of 30 µl/min for 3 minutes and allowed to dissociate for another 5 minutes before regeneration with two 25 µl injections of 3.0 M MgCl₂ at a flow rate of 50 µl/min. For proteins with high non-specific binding to the CM5 chip or mouse anti-human Fc antibody, a 1-minute injection of 2 µM human Fc after the IgG capture step was used to block unliganded mouse anti-human Fc antibody. Blank sensograms were obtained by injection of same volume of HBS-EP⁺ buffer in place of site transplant proteins. Sensograms of the concentration series were corrected with corresponding blank curves and fitted globally with Biacore Evaluation software (GE Healthcare) using a 1:1 Langmuir model of binding.

Supersite Transplants

TrueFect-Max (United BioSystems, MD) in 10 µl of Opti-MEM, and incubating for 13 min prior to transfection. 20 µl of the complex was added into each well and mixed with growing cells, and the 96-well microplate was incubated at 37°C, 5% CO₂. One day post transfection, 20 µl of enriched medium (High Glucose Dulbecco's Modified Eagle Medium plus 25% Ultra-Low IgG Fetal Bovine Serum, 2x Non-Essential Amino Acids, 1x glutamine) was added to each well, and returned to incubator for continuous culture. On days three to five post transfection, the culture was exposed to oxygen in the sterilized air once per day. Five-day post transfection, the expressed transplant protein titers in the supernatant in 96-well microplate was quantified using an Octet RED394 (Fortebio, CA). For HEK GnT- transgenic gene expression, High Glucose Dulbecco's Modified Eagle Medium was replaced with 293 FreeStyle Expression Medium (Invitrogen, CA). Kifunensine (Enzo Life Sciences, NY) at 12.5 mg/L was used in the expression of glycans V3 transplants to ensure the addition of Man₉ glycans to the recombinant proteins.

Quantification of supersite transplant expression by Octet assay

The titers of His-tagged supersite transplant proteins in expression supernatants were quantified by Octet RED394. Anti-Penta-His biosensors (Fortebio, CA) were presoaked in 1X Kinetics buffer (Fortebio, CA). 40 µl of supernatant expressed in 96-well microplate was diluted in 160 µl of PBS for analysis, with 40 µl of non-transfection culture medium diluted in 160 µl of PBS as a negative control. Standard curves were generated using serial diluted His-tagged protein with known concentration. All sensorgrams were obtained over 200 seconds at 30°C at a shake speed of 1000 rpm. The titers of supersite transplant proteins were automatically calculated using the Octet analysis software.

Quantification of supersite transplant expression by ELISA

30 µl of supernatant from each well of the 96-well microplate was mixed with 70 µl of PBS, coated onto Maxisorb (Fisher Scientific, PA) 96-well ELISA plates and incubated overnight at 4°C. The wells were washed once with wash buffer (PBS+0.05% Tween 20), and 300 µl of blocking buffer (PBS with 5% w/v dry milk) was added to each well and incubated for 2 hours at room temperature (RT). The wells were then washed 5 times with wash buffer. 100 µl of mouse Anti-Penta-His primary antibody (QIAGEN, CA) at 0.1 µg/ml was added to each well and incubated for 1 hour at RT and the wells were washed 5 times with wash buffer. Horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories Inc., PA) at 1:5,000 was added to each well and incubated for 1 hour at RT. The plate was then washed 5 times with wash buffer and developed using 3,3',5,5'-tetramethylbenzidine (TMB) (Kirkegaard & Perry Laboratories, MD) at RT for 10 min before the reaction was stopped with 180 mM HCl. The readout was measured at a wavelength of 450 nm. All samples were performed in duplicate.

Binding assay of supersite transplant by ELISA

30 µl of supernatant from each well of the 96-well microplate was mixed with 70 µl of PBS and incubated in each well of a Nickel coated 96-well ELISA plate (Thermo Scientific, IL) for two hours at room temperature (RT) or overnight at 4°C. The well was washed once with wash buffer, and then incubated with 100 µl of respective anti-HIV-1 antibody at a concentration of 10 µg/ml in PBS+0.05% Tween 20+0.2% w/v dry milk for 1 hour at RT. After 5-time wash with wash buffer, the wells were incubated with 100 µl of Horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories Inc., PA) at 1:10,000 in PBS+0.05% Tween 20+1% w/v dry milk for 30 min at RT. The wells were then washed 5 times with wash buffer and developed using TMB at RT for 10 min before addition of 180 mM HCl. The readout was measured at a wavelength of 450 nm. All samples were performed in duplicate.
Structural analysis of glycan V3 supersite

To compare interactions between the glycan V3 supersite and human antibodies that target this site, we aligned the eODmV3:PGT128 (PDB ID 3TYG) and JRFLgp120:PGT135 (PDB ID 4MJ2) complexes to the trimeric BG505 SOSIP gp40:PGT122 complex (PDB ID 4NCO) over the gp120 outer domain region. The orientations of approaching antibodies were visualized with PyMol [70] and the gp120:antibody interfaces were analyzed with program PISA [71]. Contributions of peptides and glycans inside or outside the glycan V3 region to the epitope of each antibody were compared.

Ferritin nanoparticles of glycan V3-supersite transplants

The glycan V3-supersite transplants were placed onto self-assembling Helicobacter pylori non-haem ferritin (PDB ID 3BVE) nanoparticles by fusing the supersite transplants to the N-terminus of ferritin with a flexible GGGGSG linker. The fusion proteins were expressed in 293F cells in the presence of kifunensine with protocols described above and purified with Lentil Lectin-Sepharose affinity column (GE Healthcare, NJ).

Supporting Information

Figure S1 Flowchart for computational design of supersite transplants.
(TIF)

Figure S2 V1V2-supersite transplants bind to antibodies from multiple donors. All supersite transplants which showed binding to P90 in the 96 well screen were expressed at 1 liter scale, purified and tested for binding to V1V2-directed antibodies from multiple donors by ELISA. Supersite transplants ST01 (derived from PDB ID 2ZJR) and ST04 (derived from 1V1H8) showed weak binding to several antibodies.

Figure S3 Models of glycan V3-supersite transplants in complex with antibody PGT128. The 11 glycan V3-supersite transplants with significant PGT128 reactivity were shown with grafted mini-V3 colored red and TM-align identified acceptor scaffolds colored gray and labeled with their PDB IDs. The overlapping red and gray strands indicated the location of transplantation. The glycans at Asn301 and Asn332 were colored cyan in sticks representation. Antibody PGT128 were shown with heavy chain colored blue and light chain colored green.
(TIF)

File S1 Supplementary Tables.
(PDF)

Acknowledgments

We thank B. Haynes, K. Katinger, S. Zolla-Pazner and M. Zwick for antibodies CH12, 4E10, 2F5, 3G12, 447-52D and Z13 used in antigenic characterization, X. Du and B. Zhang for production of antibodies, and members of the Structural Biology Section and Structural Bioinformatics Core Section, Vaccine Research Center, for discussions or comments on the manuscript.

Author Contributions

Conceived and designed the experiments: TZ, JZ, YY, JG GO SS PDK. Performed the experiments: TZ JZ YY JG GO SS GL AL. Analyzed the data: TZ JZ YY JG GO SS AD CS PDK. Contributed reagents/materials/analysis tools: DRB WCK MC. Contributed to the writing of the manuscript: TZ JZ YY JG GO PDK. Conceptual visualization: JS.

References

1. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204.
2. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233–236.
3. Starcich BR, Halm BH, Shaw GM, McNeely PD, Modrov S, et al. (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45: 657–648.
4. Wany R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 703–711.
5. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678–682.
6. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 907–912.
7. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimers. Science 342: 1477–1483.
8. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimere. Science 342: 1490–1494.
9. Gray ES, Moody MA, Wihiner CK, Chen X, Marshall D, et al. (2011) Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol 85: 7719–7729.
10. Mikeli I, Sather DN, Kalams SA, Altelf M, Alter G, et al. (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7: e1001253.
11. Li Y, Miqueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. J Virol 81: 1032–1034.
12. Birley JM, Lythgar E, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasma: from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651–11660.
13. Sather DN, Armann J, Chang LK, Masvronti A, Sellhorn G, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 737–750.
14. Sinek MD, Rida W, Pridfy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7373–7348.
15. Stamatakis L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866–870.
16. Hraber P, Seaman MS, Bailey RT, Mascola JR, Montefiori DC, et al. (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28: 163–169.
17. Ofek G, Genuaga E, Schier FR, Skinner J, Baker D, et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 107: 17808–17817.
18. Correia BE, Ban YE, Holmes MA, Xu H, Ellington K, et al. (2010) Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116–1126.
19. Azotei ML, Correia BE, Ban YE, Carrico C, Kaluzynsky O, et al. (2011) Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334: 573–576.
20. Mcellan JS, Correia BE, Chen M, Yang Y, Graham BS, et al. (2011) Design and characterization of epitope-scaffold immunogens that present the matovizumab epitope from respiratory syncytial virus. J Mol Biol 409: 853–866.
21. Stanfield RL, Julien JP, Pejchal R, Gach JS, Zuck MB, et al. (2011) Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope. Journal of molecular biology 414: 460–476.
22. Azotei ML, Ban YE, Julien JP, Bryson S, Schroeter A, et al. (2012) Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol 415: 175–192.
23. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, et al. (2014) Proof of principle for epitope-focused vaccine design. Nature 507: 201–206.
24. Kwong PD, Mascola JR (2012) Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunol 37: 412–425.
25. Kung L, Lee JH, Doores KJ, Murin CD, Julien JP, et al. (2013) Superpotency of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20: 796–803.
26. Zhang Y, Skolnick J (2009) TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 37: 2302–2309.
27. Jakuschev S, Hoffmann D (2009) A novel algorithm for macromolecular epitope matching. Algorithms 2: 498–517.
49. Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, et al. (2008) Novel type

47. Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, et al. (2009)

45. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, et al. (2013) Asymmetric

38. Kobayashi K, Kikuno I, Kuroha K, Saito K, Ito K, et al. (2010) Structural basis

37. Samara NL, Datta AB, Berndsen CE, Zhang XB, Yao TT, et al. (2010) Delineating antibody recognition in penicillin sera from patterns of HIV-1 isolate neutralization. Science 340: 751–756.

36. Morris L, Chen X, Alam M, Tomaras G, Zhang R, et al. (2011) Isolation of a broadly neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293–7305.

35. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, et al. (2009) A conformational switch in human immunodeficiency virus gp120 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83: 8451–8462.

34. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody HE10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp120. Immunity 22: 163–173.

33. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp120. J Virol 86: 9431–9462.

32. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved antigenic site on gp120 of human immunodeficiency virus type 1 is recognized by a conformation-dependent antibody. Nature 365: 727–730.

31. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins 47: 466–470.

30. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, et al. (1994) Cross-reactivity of broadly neutralizing antibodies with related human immunodeficiency virus type 1 isolates induced by the gp120 sequence ELDIIKVAS. J Virol 68: 4031–4034.

29. Zwicker MB, Labrijn AF, Wang M, Spendeilhauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp120. J Virol 75: 10892–10905.

28. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.

27. Song X, Huang X, Chen X, Tsao CY, Morris L, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9996–10009.

26. Walker LM, Huber M, Doores JK, Falkowski E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470.

25. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336–343.

24. Pancera M, Shaloudi-U-Hussan S, Doria-Rose NA, McLellan JS, Bailey RT, et al. (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20: 26–38.

23. Julien JP, Lee JH, Cupo A, Merin CD, Derking R, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 110: 4351–4356.

22. Harm MJ, Wilson DN, Schluenzen F, Connell SR, Stachelhaus T, et al. (2000) Translational regulation via L11: molecular switches on the ribosome turned on and off by distoepton and micrococin. Mol Cell 30: 26–38.

21. Gerhardt S, Abbott WM, Hargreaves D, Pauprit RA, Davies RA, et al. (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 394: 901–921.

20. Badger J, Sauder JM, Adams JM, Antonysamy S, Bain K, et al. (2005) Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins 60: 787–796.

19. Steiglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, et al. (2000) Novel type of Ras effector interaction established between tumour suppressor Nore1A and Ras switch II. EMBO J 17: 2995–2005.

18. Hasegawa H, Holm L. (2009) Advances and pitfalls of protein structural alignment. Curr Opin Struct Biol 19: 341–348.

17. Zhou H, Zhou Y (2002) Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction. Protein Sci 11: 2714–2726.

16. Muster T, Guine F, Trkola A, Partsch M, Klima A, et al. (1994) Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp120 sequence ELDIIKVAS. J Virol 68: 4031–4034.